Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it
Reviewed 14 sourcesPublished by PepVault
Aleniglipron is Structure Therapeutics' daily GLP-1 pill in testing: its phase 2 numbers, every trial, and what its shot-to-pill SWITCH trial must beat.

- Last reviewed
- Sources
- 14
- Questions
- 8
- Compounds
- 3
The short answer
Aleniglipron is Structure Therapeutics' once-daily GLP-1 pill, still in trials and approved nowhere. In phase 2, weight fell up to 16.3% more than on placebo at 44 weeks. Its SWITCH trial moves people from a GLP-1 shot to the pill for 12 weeks; Structure expects the data in Q4 2026. The bar: orforglipron kept 75 to 79% of the shot's loss for a year in people whose weight had plateaued.
Evidence: Early for aleniglipron: company-run phase 2 trials in people (ACCESS, 230 people, published; ACCESS II, 85 people, and a 72-week open-label extension, company releases), phase 3 enrolling, SWITCH not yet reported. The bar comes from large phase 3 trials of other drugs.

What is aleniglipron?
Aleniglipron is an experimental weight-loss pill taken once a day, made by Structure Therapeutics of San Francisco1. Its code name is GSBR-1290, and the trials are registered under Gasherbrum Bio, which the registry lists as a wholly owned subsidiary of Structure, so the two names are the same program14.
It belongs to the same class as Wegovy and Zepbound: a GLP-1 receptor agonist, a drug that switches on the body's receptor for GLP-1, the gut hormone that helps set appetite. The difference is the molecule. Semaglutide and tirzepatide are peptides, chains of amino acids that the stomach breaks down, which is why they are injected or, for the Wegovy pill, need strict fasting rules. Aleniglipron is a small molecule, a compact chemical built to survive the gut and be absorbed as a pill4. It is in the same family as Lilly's orforglipron, which the FDA approved as Foundayo in April 2026.
As of November 20, 2026, aleniglipron is approved nowhere and is available only inside clinical trials. Its phase 3 program, the large trials a drug needs before approval, opened its first sites in July 2026, per the registry; Structure dates the start to August1910.

PepVault for iPhone
Keep your protocol in PepVault
After a switch, the weight is the result that counts. PepVault's weight log draws your trend week by week, so a slow drift up shows early, while there is still time to talk it over with your prescriber.
7 days free on the yearly plan for new subscribers.
How does aleniglipron work?
It does what the GLP-1 shots do, from a pill: it acts like GLP-1, the hormone that lowers appetite, makes a meal feel filling sooner and slows how fast the stomach empties4. Structure shaped the molecule to fit the receptor's own structure and describes it as selective and biased: it acts on the GLP-1 receptor alone and favours some of the receptor's signals over others4.
In the trials it is swallowed once a day and stepped up every four weeks to a target dose, the same slow climb the shots use to let the stomach adjust4. The phase 3 trials start at 2.5 mg and climb to 45, 90 or 180 mg a day1.
How much weight did people lose on aleniglipron?
Between 8% and 16% of body weight beyond placebo, rising with the dose. ACCESS, the main phase 2b trial, gave 230 adults 45, 90 or 120 mg a day or a placebo pill for 36 weeks; on 120 mg, weight fell 12.1% against 0.8% on placebo, and 70% of people lost at least 10%4. ACCESS II tested higher doses in 85 people for 44 weeks3.
| Trial | People | Weeks | Top dose | Weight change on the drug | Beyond placebo |
|---|---|---|---|---|---|
| ACCESS (phase 2b)4 | 230 | 36 | 120 mg | -12.1% | -11.3% |
| ACCESS II (phase 2)3 | 85 | 44 | 180 mg | -15.3% | -16.3% |
| ACCESS II (phase 2)3 | 85 | 44 | 240 mg | -15.0% | -16.0% |
| ACCESS open-label extension2 | ACCESS completers | 72 | up to 180 mg | -16.2% (from the 120 mg arm) | no placebo group |
The weight was still falling at the end of each trial: Structure reports no plateau at 36, 44 or 72 weeks in the top dose groups234. In the extension, more than a third of people in the two highest groups lost over 20% of their weight by week 722. These are small phase 2 trials and the extension has no placebo group (it is open-label: everyone knows they take the drug), so the phase 3 trials will give the firm numbers.
What side effects came with aleniglipron in the trials?
The usual GLP-1 ones, in the stomach and gut, mostly mild to moderate and mostly early. In ACCESS, nausea was reported by 65% of people on 120 mg against 21% on placebo, and vomiting by 32% against 5%4. They eased over time, and vomiting rarely came back after a paused dose was restarted4.
The start mattered. With a 5 mg first step, 10.4% of people on aleniglipron in ACCESS stopped because of side effects4. Fewer than 5% stopped across the 72-week extension, and the placebo group that started there at 2.5 mg had fewer stomach side effects than the 5 mg start in ACCESS2. The phase 3 trials now use the 2.5 mg start1. ACCESS found no drug-caused liver injury, and the liver enzyme rises that did occur went back to normal without stopping the drug4.
What is the aleniglipron SWITCH trial testing?
Whether people who already lost weight on an approved GLP-1 injection can move to the aleniglipron pill and keep the weight off1. Structure describes it as testing the move from an injectable GLP-1 receptor agonist to once-daily aleniglipron for weight-loss maintenance, comparing different aleniglipron starting doses over 12 weeks1. Structure calls it a phase 1 study2.
The starting dose is the practical question. Someone coming off a full-dose shot is already used to a GLP-1, so climbing from 2.5 mg again would leave weeks on a weak dose. Lilly asked the same question with orforglipron and moved people straight to 12 mg (9 mg in today's tablets), skipping the first steps: about one in ten (10.5% and 9.5% in the two groups) had nausea, vomiting or diarrhea in the first four weeks, mostly mild to moderate, and none needed a lower dose11.
Structure has not published how many people are in SWITCH, which shots they came from, or the doses tested, and we found no SWITCH record on ClinicalTrials.gov: none of the 11 aleniglipron records there is a switch study14. This page fills those in when Structure reports.
What would count as a good SWITCH result?
Weight that holds steady for the 12 weeks. The comparison is what happens when the shot simply stops: in the withdrawal trials, weight came back within months. The one switch trial with results, orforglipron's ATTAIN-MAINTAIN, sets the bar for a pill11.
| Trial | What happened after the shot | Weeks | Result |
|---|---|---|---|
| SURMOUNT-412 | Tirzepatide stopped (placebo) | 52 | Weight up 14.0% (kept on tirzepatide: down a further 5.5%) |
| STEP 1 extension13 | Semaglutide stopped, no treatment | 52 | Regained 11.6 of the 17.3 points lost, about two-thirds |
| ATTAIN-MAINTAIN, from tirzepatide11 | Orforglipron pill vs placebo pill | 52 | Kept 74.7% of the loss on the pill vs 49.2% on placebo (people whose weight had plateaued) |
| ATTAIN-MAINTAIN, from semaglutide11 | Orforglipron pill vs placebo pill | 52 | Kept 79.3% of the loss on the pill vs 37.6% on placebo (people whose weight had plateaued) |
ATTAIN-MAINTAIN's early weeks are the closest match to SWITCH's 12. Among people who stayed on the pill, those coming off tirzepatide were 21.5% below their original weight at the switch and 19.0% below it at week 24; those coming off semaglutide went from 16.5% to 16.3%, keeping almost all of it11. So a strong SWITCH result keeps weight within a point or two of where the shot left it, and a starting dose that skips the slow climb without a wave of nausea.
The number to watch beside the weight is how many people stop the pill because of side effects. In ATTAIN-MAINTAIN that was 4.8% to 7.3%11; aleniglipron's 72-week extension came in under 5%2. A 12-week trial is short, so even a clean result shows the first step of a switch, not a year of maintenance.
After a switch, the weight is the result that counts. PepVault's weight log draws your trend week by week, so a slow drift up shows early, while there is still time to talk it over with your prescriber. Track your weight in PepVault
Which aleniglipron trials are in the registry?
Eleven, all sponsored by Gasherbrum Bio, as of November 20, 202614. Dates are primary completion, per ClinicalTrials.gov: when the main measurement ends, not when results are released. "Est." marks the sponsor's estimate; the rest are actual dates.
| Trial | Phase | People | Primary completion | Status |
|---|---|---|---|---|
| NCT05762471, adults with overweight or obesity, and with type 2 diabetes | 1b/2a | 142 | Apr 2024 | Completed |
| NCT05893043, Japanese and non-Japanese healthy adults | 1 | 18 | Jun 2023 | Completed |
| NCT06139055, healthy adults with overweight or obesity | 1 | 70 | Mar 2024 (est.) | Unknown |
| NCT06693843, ACCESS5 | 2b | 230 | Oct 2025 | Completed |
| NCT06703021, ACCESS II6 | 2 | 85 | Jan 2026 | Completed |
| NCT07169942, body composition7 | 2 | 71 | Sep 2026 | Completed |
| NCT07400588, type 2 diabetes8 | 2 | 58 | Sep 2026 | Completed |
| NCT07654361, ACCOMPLISH-19 | 3 | 3,600 (planned) | Sep 2028 (est.) | Recruiting |
| NCT07654374, ACCOMPLISH-2, with type 2 diabetes10 | 3 | 1,100 (planned) | Sep 2028 (est.) | Recruiting |
| NCT07872033, liver impairment | 1 | 36 (planned) | Aug 2027 (est.) | Recruiting |
| NCT07946068, kidney impairment | 1 | 16 (planned) | Mar 2027 (est.) | Not yet recruiting |
The two ACCOMPLISH trials are the ones that could lead to approval. Both compare 45, 90 or 180 mg a day with placebo, and their primary endpoint, the main measure each trial is built to answer, is the change in body weight at week 76910.
When will aleniglipron's next results come out?
Structure expects three readouts in the fourth quarter of 2026: SWITCH, the 44-week body composition trial (how much of the weight lost is fat) and the 30-week type 2 diabetes trial1. The body composition and diabetes trials have finished their main measurements, per ClinicalTrials.gov78. Structure expects topline phase 3 results in the second half of 20281.
Has SWITCH reported yet? Not as of November 20, 2026. Structure's latest update, on November 9, still lists it as expected in Q4 2026, and its two posters at ObesityWeek (November 14 to 17), scheduled for November 15, covered the extension and the dose-ranging results across the ACCESS trials, not SWITCH1. This page is updated when the result lands.
Until then, the one pill with switch data is orforglipron, sold as Foundayo. Moving between GLP-1 medicines, and the dose to start on, is a plan made with the prescriber.
Moving from a weekly shot to a daily pill? In PepVault you finish the shot's plan and start the pill's, so both stay in one history beside your weight. Log it in PepVault
Sources
- Structure Therapeutics. Third quarter 2026 financial results and recent highlights (Form 8-K, Exhibit 99.1). November 9, 2026. sec.gov
- Structure Therapeutics. Positive clinical data across oral small molecule amylin and GLP-1 programs: ACCESS open-label extension, 72 weeks (Form 8-K, Exhibit 99.1). September 8, 2026. sec.gov
- Structure Therapeutics. Positive topline data from phase 2 ACCESS II trial of aleniglipron, 44 weeks (Form 8-K, Exhibit 99.1). March 16, 2026. sec.gov
- Rosenstock J et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2026;32(8):2941-2947. PubMed 42249138
- ClinicalTrials.gov. NCT06693843: ACCESS, a phase 2b dose-range finding study of aleniglipron (GSBR-1290). clinicaltrials.gov
- ClinicalTrials.gov. NCT06703021: ACCESS II, a dose-range study of aleniglipron (GSBR-1290). clinicaltrials.gov
- ClinicalTrials.gov. NCT07169942: aleniglipron phase 2 body composition study. clinicaltrials.gov
- ClinicalTrials.gov. NCT07400588: aleniglipron phase 2 in type 2 diabetes mellitus. clinicaltrials.gov
- ClinicalTrials.gov. NCT07654361: ACCOMPLISH-1, aleniglipron in obesity or overweight with a weight-related comorbidity. clinicaltrials.gov
- ClinicalTrials.gov. NCT07654374: ACCOMPLISH-2, aleniglipron in obesity or overweight with type 2 diabetes. clinicaltrials.gov
- Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679-2687. PubMed 42120723
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. PubMed 38078870
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
- ClinicalTrials.gov. All studies with lead sponsor Gasherbrum Bio, Inc. (a wholly owned subsidiary of Structure Therapeutics), read November 20, 2026. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.